a:5:{s:8:"template";s:12592:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<title>{{ keyword }}</title>
<meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
<meta content="width=device-width,initial-scale=1.0" name="viewport"/>
<link href="http://fonts.googleapis.com/css?family=Yanone+Kaffeesatz:400,700" rel="stylesheet" type="text/css"/>
<link href="http://fonts.googleapis.com/css?family=Oswald" rel="stylesheet" type="text/css"/>
<style rel="stylesheet" type="text/css">@charset "utf-8";body,div,footer,form,h1,h2,h3,header,html,img,li,nav,p,span,time,ul{margin:0;padding:0;border:0;outline:0;font-size:100%;vertical-align:baseline;background:0 0}body{line-height:1}footer,header,nav{display:block}nav ul{list-style:none}a{margin:0;padding:0;font-size:100%;vertical-align:baseline;background:0 0}a{margin:0;padding:0;font-size:100%;vertical-align:baseline;background:0 0}input{vertical-align:middle}#sb-site,.sb-slidebar,body,html{margin:0;padding:0;-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}body,html{width:100%;overflow-x:hidden}html{height:100%}body{min-height:100%;height:auto;position:relative}#sb-site{width:100%;position:relative;z-index:1}.sb-slidebar{height:100%;overflow-y:auto;position:fixed;top:0;z-index:0;display:none;background-color:#fff;-webkit-transform:translate(0)}.sb-right{right:0}.sb-slidebar{width:30%}@media (max-width:480px){.sb-slidebar{width:70%}}@media (min-width:481px){.sb-slidebar{width:55%}}@media (min-width:768px){.sb-slidebar{width:40%}}@media (min-width:992px){.sb-slidebar{width:30%}}@media (min-width:1200px){.sb-slidebar{width:20%}}#sb-site,.sb-slidebar{-webkit-transition:-webkit-transform .4s ease;-moz-transition:-moz-transform .4s ease;-o-transition:-o-transform .4s ease;transition:transform .4s ease;-webkit-transition-property:-webkit-transform,left,right;-webkit-backface-visibility:hidden} @font-face{font-family:'Yanone Kaffeesatz';font-style:normal;font-weight:700;src:url(http://fonts.gstatic.com/s/yanonekaffeesatz/v14/3y9I6aknfjLm_3lMKjiMgmUUYBs04aUXNxt9gW2LIftoEdKZd2GP.ttf) format('truetype')}body{margin:0;font-family:'Century Gothic',Helvetica,Arial,Sans-serif;font-size:14px;line-height:20px;text-align:left;vertical-align:top;background:#fff;color:#000}body,form,h1,h2,h3,p{margin:0;padding:0}h1{font-size:24px;padding:0 0 10px 0}a:link,a:visited{text-decoration:none;color:#ef717d}a:hover{color:#f28b2e}p{padding:0 0 10px}.clear{clear:both}#sb-site{}#wrapper{background:#fff;margin:0 auto 0 auto;max-width:1000px;text-align:left;width:100%}#innerWrap{padding:0 30px;width:auto}#mainHd{min-height:163px;width:100%}#mainHd h1{float:left;height:163px;margin:0;text-indent:-9999px;width:234px}#mainHd h1 a{display:block;height:163px;width:234px}#mainHd .menu{border-top:6px double #999b9a;border-bottom:6px double #999b9a;float:right;font-family:'Yanone Kaffeesatz';font-size:44px;font-weight:700;line-height:44px;list-style:none;margin:25px 0 10px;padding:5px 0;max-width:706px;text-transform:uppercase;width:auto}#mainHd .menu li{float:left;list-style:none;position:relative}#mainHd .menu li a{padding:0 12px}#mainHd .menu li ul{display:none;position:absolute;top:44px;left:0;width:180px;background:#fff;box-shadow:0 0 4px #606060;z-index:99}#mainHd .menu li:hover ul{display:block}#mainHd .menu li ul li{float:none;font-size:24px;line-height:24px;margin:0;padding:0}#mainHd .menu li ul li a{display:block;padding:10px 0 10px 15px}#mainHd .menu li:nth-child(6n-5) a{color:#ef7163}#mainHd .menu li:nth-child(6n-5) a:hover{color:#999b9a}#mainHd .menu li:nth-child(6n-4) a,#mainHd .menu li:nth-child(6n-4) ul li a{color:#ef717d}#mainHd .menu li:nth-child(6n-4) a:hover,#mainHd .menu li:nth-child(6n-4) ul li a:hover{color:#999b9a}#mainHd .menu li:nth-child(6n-3) a{color:#f49081}#mainHd .menu li:nth-child(6n-3) a:hover{color:#999b9a}#mainHd .menu li:nth-child(6n-2) a{color:#f28b2e}#mainHd .menu li:nth-child(6n-2) a:hover{color:#999b9a}#mainHd .menu li:nth-child(6n-1) a{color:#fac829}#mainHd .menu li:nth-child(6n-1) a:hover{color:#999b9a}  .menu{border-top:1px solid #ccc;clear:both;font-family:'Yanone Kaffeesatz';font-size:30px;font-weight:700;line-height:30px;list-style:none;padding-top:5px;text-align:right;text-transform:uppercase}.sb-slidebar .menu li{border-bottom:1px solid #ccc;padding:0 0 5px;margin-bottom:5px}.sb-slidebar .menu ul{list-style:none;padding-top:5px}.sb-slidebar .menu ul li{border-bottom:none;font-size:24px;line-height:24px;padding:0 0 0;font-weight:400}.sb-slidebar .menu ul li a{color:#7bd3c7}.sb-slidebar .menu ul li a:hover{color:#5fbbb6}.sb-toggle-right{display:none;cursor:pointer;float:right;margin:0;padding-top:30px;width:25px}.sb-toggle-right .navicon-line{background:#ef717d;display:block;height:5px;margin:0 auto 5px;width:25px}.sb-toggle-right:hover .navicon-line{background:#5fbbb6}#mainFoot{background:#f49081;box-sizing:border-box;clear:both;color:#fff;padding:30px 2% 0 2%;width:100%}#leftFt{box-sizing:border-box;float:left;max-width:470px;padding-right:15px;width:50%}#leftFt #ftNav .menu{color:#fff;list-style:none;float:left;border-top:6px double #fff;border-bottom:6px double #fff;font-family:'Yanone Kaffeesatz';font-size:22px;font-weight:700;line-height:22px;padding:5px 0;margin-bottom:15px;text-transform:uppercase;width:100%}#leftFt #ftNav .menu li{float:left;padding:2px 5px 2px 0;border-right:3px solid #fff;margin-right:5px}#leftFt #ftNav .menu li:last-child{padding-right:0;border-right:none;margin-right:0}#leftFt #ftNav .menu li a{color:#fff}#leftFt #ftNav .menu li a:hover{color:#f8d4cf}#leftFt .socialIcons{color:#f8d4cf;font-family:'Yanone Kaffeesatz';font-size:28px;font-weight:700;line-height:28px;list-style:none;float:left;height:33px;text-transform:uppercase;vertical-align:bottom;width:410px}#leftFt .socialIcons::before{content:"DON'T BE ANTI-SOCIAL:"}#leftFt .socialIcons li a{background-position:center bottom;background-repeat:no-repeat;display:block;height:32px;width:32px}#leftFt .socialIcons li a:hover{background-position:center top}#rightFt{box-sizing:border-box;float:right;max-width:470px;padding-left:15px;width:50%}#rightFt::after{clear:both}#rightFt #bioPic{box-sizing:border-box;float:right;height:169px;margin:0 0 10px 15px;padding:5px;width:147px}#rightFt #bioPic img{height:auto;max-width:100%}#rightFt h3{color:#fff;font-family:havana;font-size:57px;font-weight:400;line-height:57px}#rightFt h3 span{color:#fac829}#mainFoot p{line-height:18px}p.copy{clear:both;color:#fff;font-size:10px;line-height:12px;margin:0;padding:10px 0 0}.copy a{color:#606060}.copy a:hover{color:#fff}#slider{margin-bottom:30px}#recBlog{background:#f7f5ef box-sizing:border-box;padding:20px 20px 40px;margin-bottom:20px;float:right;min-height:272px;width:74%}#recBlog h2{color:#ef717d;font-family:'Yanone Kaffeesatz';font-size:34px;font-weight:700;line-height:34px;margin:0 0 5px;padding:0;text-transform:uppercase;width:100%}#recBlog p.date{font-size:12px;line-height:16px}#recBlog .more{color:#fff;float:right;font-family:'Yanone Kaffeesatz';font-size:26px;font-weight:700;line-height:26px;text-transform:uppercase}#recBlog .more a{background:#ef717d;color:#fff;display:block;padding:5px 10px;width:auto}#recBlog .more a:hover{background:#f28b2e}#newsletter{background:#ef717d;box-sizing:border-box;color:#fff;float:left;margin-bottom:20px;padding:20px 20px 50px;width:24%}#newsletter h2{font-family:havana;font-size:48px;font-weight:400;line-height:48px;margin:0;padding:0}#newsletter h3{font-family:'Yanone Kaffeesatz';font-size:24px;line-height:24px;margin:0 0 15px;text-align:right;text-transform:uppercase}#newsletter input[type=email],#newsletter input[type=text]{background:#f799a2;border:none;box-sizing:border-box;height:32px;margin-bottom:10px;padding:5px 10px;width:100%}#newsletter input[type=submit]{background:#fac829;border:none;color:#fff;font-family:'Yanone Kaffeesatz';font-size:26px;font-weight:700;float:right;letter-spacing:normal;line-height:26px;padding:5px 10px;text-transform:uppercase;width:auto}#newsletter input[type=submit]:hover{background:#b1e2dc}#pco,#shco{box-sizing:border-box;float:left;padding-bottom:40px;width:50%}#pco{padding-right:10px}#pco h3{border-top:6px double #999b9a;border-bottom:6px double #999b9a;color:#f28b2e;font-family:'Yanone Kaffeesatz';font-family:havana;font-size:44px;font-weight:400;line-height:44px;margin:0 0 15px;padding:5px 0;text-align:center;width:100%}#shco{padding-left:10px}#shco h3{border-top:6px double #999b9a;border-bottom:6px double #999b9a;color:#5fbbb6;font-family:havana;font-size:44px;font-weight:400;line-height:44px;margin:0 0 15px;padding:5px 0;text-align:center;width:100%}.releaseBlock{box-sizing:border-box;max-width:320px;float:left;height:auto;margin:0;padding:10px;width:50%}.releaseBlock img{height:auto;max-width:100%}input[type=email]{background:#d8d8d8;border:none;box-sizing:border-box;height:40px;margin:0 0 15px;padding:10px 15px;width:100%}::-webkit-input-placeholder{color:#fff}:-moz-placeholder{color:#fff}::-moz-placeholder{color:#fff}:-ms-input-placeholder{color:#fff}.rslides{box-sizing:border-box;position:relative;list-style:none;width:100%;padding:0;margin:0;z-index:0}.rslides li{-webkit-backface-visibility:hidden;position:absolute;display:none;width:100%;left:0;top:0;z-index:0}.rslides li:first-child{position:relative;display:block;float:left}.rslides img{display:block;height:auto;float:left;width:100%;border:0}@media screen and (max-width:960px){#sb-site{background:#fff}#wrapper{padding:0;width:100%}#innerWrap{padding:0 5%;width:90%}#mainHd .menu{font-size:30px;line-height:30px}}@media screen and (max-width:865px){#mainHd{margin-bottom:20px}#mainHd h1{float:none;margin:0 auto}#mainHd .menu{float:left;font-size:44px;line-height:44px;margin:10px auto;max-width:100%;width:100%}#mainHd .menu li:last-child::after{clear:both}#mainHd .socialIcons{padding:0}}@media screen and (max-width:768px){#mainHd h1{float:left;margin:0}#mainHd #searchform,#mainHd .menu,#mainHd .socialIcons{display:none}.sb-toggle-right{display:block}#leftFt .socialIcons{display:none}#leftFt,#rightFt{float:none;margin:0 auto 20px;width:100%;max-width:100%}#newsletter,#recBlog{width:48%}#pco h3,#shco h3{font-size:30px;line-height:30px}.releaseBlock{float:none;margin:0 auto;width:100%}}@media screen and (max-width:480px){#newsletter,#recBlog{float:none;width:100%}#pco,#shco{float:none;padding:0 0 30px;width:100%}}@media only screen and (-webkit-min-device-pixel-ratio:2),only screen and (min--moz-device-pixel-ratio:2),only screen and (-o-min-device-pixel-ratio:2/1),only screen and (min-device-pixel-ratio:2){#mainHd h1{-webkit-background-size:234px 163px;-moz-background-size:234px 163px;-o-background-size:234px 163px;background-size:234px 163px} @font-face{font-family:Oswald;font-style:normal;font-weight:400;src:url(http://fonts.gstatic.com/s/oswald/v31/TK3_WkUHHAIjg75cFRf3bXL8LICs1_FvsUZiYA.ttf) format('truetype')}}</style>
</head>
<body>
<div id="sb-site">
<div id="wrapper">
<div id="innerWrap">
<header id="mainHd">
<h1>{{ keyword }}</h1>
<ul class="menu" id="menu-main-navigation-menu">
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-1995" id="menu-item-1995"><a href="#">{{ keyword }}</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page current_page_parent menu-item-1994" id="menu-item-1994"><a href="#">Blog</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1998" id="menu-item-1998"><a href="#">About</a></li>
<li class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-1999" id="menu-item-1999"><a href="#">Tutorials</a></li>
</ul>
<div class="clear"></div>
</header>
{{ text }}
<p>.</p>
{{ links }}
</div>
<footer id="mainFoot">
<div id="leftFt">
<nav id="ftNav">
<ul class="menu" id="menu-footer-navigation-menu">
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2025" id="menu-item-2025"><a href="#">Terms of Use</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2015" id="menu-item-2015"><a href="#">Contact</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2027" id="menu-item-2027"><a href="#">Info</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-2014" id="menu-item-2014"><a href="#">Additional Services</a></li>
</ul> </nav>
<div class="clear"></div>
<p class="copy">{{ keyword }}</p>
</div>
<div id="rightFt">
<div id="bioPic"></div>
<h3>{{ keyword }}</h3>
</div>
<div class="clear"></div>
</footer>
</div>
</div>
</body>
</html>";s:4:"text";s:10596:"<p>CRISPR Therapeutics (NASDAQ:CRSP) has a compelling scientific story, but has yet to turn it into drugs for sale. The story is gene editing, one of the most exciting concepts of the coming decade. But what matters are drugs that can be sold to people that make them better. Unprecedented. CTX130 is a healthy donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 70, or CD70, an antigen expressed on various solid tumors and hematologic malignancies. CRSP has two treatments in clinical trials. CRSP is a reasonable speculation. Research and development costs are expensed as incurred. We expect our expenses to increase compared to prior periods in . © Source: Catalin Rusnac/ShutterStock.com, Most Americans don't know these lucrative Social Security "secrets". Sep 03, 2020. </p> <p>Actual performance and results may differ materially from those projected or suggested in the forward … Nations will probably collectively buy successful coronavirus treatments in case a different strain surfaces. </p> <p>Cells are first extracted from the patient. Crispr Therapeutics Ag has 13 trademark applications. Recently, we re-initiated dosing patients in our Phase 1/2 open-label clinical trials of CTX001 for transfusion-dependent beta thalassemia and severe sickle cell disease (CLIMB THAL-111 and CLIMB SCD-121). These risks and uncertainties include, but are not limited to, the risk that any one or more of Intellia’s product candidates will not be successfully developed and commercialized, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or development of Intellia’s product candidates, the risk that the results of previously conducted studies involving similar product candidates will not be repeated or observed in ongoing or future studies involving current product candidates, the risk that Intellia’s collaborations with Novartis or Regeneron will not continue or will not be successful, and risks related to Intellia’s ability to protect and maintain its intellectual property position. Spread your bets widely enough and you’re likely to find a gusher. We have predominantly incurred losses and cumulative negative cash flows from operations since our inception, and as of June 30, 2020, we had an accumulated deficit of $374.1 million. Except for activities we perform in connection with our collaboration with Vertex, as well as certain arrangements we had with Casebia prior to the Bayer Transaction, we do not track research and development costs on a program-by-program basis. Just don’t put money into it you can’t afford to lose. In a previous article on Gilead, I. Regeneron is developing a single treatment consisting of two antibodies. BASEL, Switzerland, CAMBRIDGE, Mass., BERKELEY, Calif. and DUBLIN, Ireland, Dec. 16, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics (NASDAQ:NTLA), Caribou Biosciences, and ERS Genomics announced that the companies and their licensors have entered into a global cross-consent and invention management agreement for the foundational intellectual property covering CRISPR/Cas9 gene editing technology. Our modular approach enables us to optimize the power and versatility of the CRISPR/Cas9 technology and, importantly, allows us to rapidly develop therapeutics for numerous diseases that currently have limited treatment options. Revenue recognized for the six months ended June 30, 2020 and 2019, respectively, was not material.                 Subscriber Agreement & Terms of Use, The capitalized amounts are expensed as the related goods are delivered or the services are performed. . Further, some people with weak immune systems may not be able to ever receive vaccines. CTX120. Our lead candidate, CTX110, is a healthy donor-derived gene-edited allogeneic CAR-T therapy targeting cluster differentiation 19, or CD19, for the treatment of CD19+ malignancies. We and Vertex are also investigating CTX001 in a Phase 1/2 open-label clinical trial, CLIMB SCD-121, that is designed to assess the safety and efficacy of a single dose of CTX001 in patients ages 18 to 35 with severe SCD. CRSP does have a financial runway for proving itself. The multi-center, open-label clinical trial is designed to enroll up to 88 patients and investigate several dose levels of CTX120. We maintain three broad strategic partnerships to develop gene editing-based therapeutics in specific disease areas. Trademark applications and grants for Crispr Therapeutics Ag. </p> <p>As of this writing he owned no shares in companies mentioned in this story. Collaboration revenue for the three months ended June 30, 2020 and 2019, respectively, was not material. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the Company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. The technique CRSP was built around may not be the final word in gene editing. </p> <p>These risks and uncertainties include, among others: uncertainties regarding the intellectual property protection for our technology and intellectual property belonging to third parties; uncertainties inherent in the initiation and completion of preclinical studies for the Company’s product candidates; availability and timing of results from preclinical studies; whether results from a preclinical trial will be predictive of future results of the future trials; expectations for regulatory approvals to conduct trials or to market products; and those risks and uncertainties described in Item 1A under the heading “Risk Factors” in the company’s most recent quarterly report on Form 10-Q, and in any other subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC’s website at www.sec.gov. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The first two patients in the trial were treated sequentially and, following data from the initial two patients indicating successful dosing and engraftment, the trial opened for broader concurrent enrollment. Nonrefundable advance payments for research and development goods or services to be received in the future are deferred and capitalized. Investor Contact: Susan Kim +1-617-307-7503 susan.kim@crisprtx.com. For additional information please visit www.ersgenomics.com. The information contained in this press release is provided by the company as of the date hereof, and, except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking information contained in this press release. Research and development activities are central to our business model. Other income was $5.6 million for the six months ended June 30, 2020, compared to $1.5 million of income for the six months ended June 30, 2019. One is CTX-001, a treatment for B-thalassemia. And of course, particularly if there is a second wave of the virus in the fall and winter, millions of people are likely to have it for at least a couple of months after vaccines are introduced. At this time, we cannot reasonably estimate or know the nature, timing or estimated costs of the efforts that will be necessary to complete the development of any product candidates we may identify and develop.  CLIMB SCD-121 is designed to enroll up to 45 patients and follow patients for approximately two years after infusion. As a result of the coronavirus pandemic, we have experienced, and may further experience, disruptions, pauses and/or delays that have and could further adversely impact our business operations, including the conduct of our clinical trials and other research and development operations in accordance with previously-announced timelines. Dana Blankenhorn has been a financial and technology journalist since 1978. In addition, we are developing our own portfolio of CAR-T cell product candidates based on our gene-editing technology. 7 Hot Food Stocks to Buy for Tasty Returns, 10 Long-Term Stocks to Buy to Profit From Secular Trends, during its second-quarter conference call, was previously able to develop antibodies, Why Everyone Is Investing in 5G All WRONG, America’s #1 Stock Picker Reveals His Next 1,000% Winner, Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company, Radical New Battery Could Dismantle Oil Markets. San Francisco Office. </p> <p>We have not generated any revenue to date from product sales and do not expect to do so in the near future. With the exception of the year ended December 31, 2019, we have incurred significant net operating losses each year since our inception and expect to continue to incur net operating losses for the foreseeable future. It has minimal debt, it can sell stock, and it has a development partner, Vertex Pharmaceuticals (NASDAQ:VRTX). Like us on Facebook to see similar stories, Trump says Whitmer didn't say 'thank you' after thwarted kidnapped plot. She did thank law enforcement, Save Hundreds of Calories on a Starbucks Peppermint Mocha With These Simple Hacks, I'm very optimistic that we will see a successful vaccine for the, West Pharmaceutical makes stoppers, seals and syringe components. </p> <p>CRISPR Therapeutics explicitly disclaims any obligation to update any forward-looking statements. Connect with friends faster than ever with the new Facebook app. And importantly, it also develops "custom solutions" for injectable drugs. COMTEX_368512828/2041/2020-07-27T16:43:47. CRISPR Therapeutics 455 Mission Bay Boulevard South San Francisco, CA 94158. </p> <p>In the fourth quarter of 2019, we released preliminary clinical data from the first patient treated with CTX001 in the ongoing Phase 1/2 clinical trial in TDT. </p> <p>It is looking to release data on the antibodies by the end of September. A/F Protein Inc. (fka Marifrost, Inc) Acacia Biosciences, Inc. Acrigen Biosciences, Inc. Algen … Based on this early data Piper Sandlin made CRSP a “top pick” in June, when its market cap was about $4.5 billion. Given all of these points, buying GILD stock definitely makes sense. </p> <p>We are a leading gene editing company focused on the development of CRISPR/Cas9-based therapeutics. </p> <p>The latest application filed is for "GUIDESPACE" Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders. </p>";s:7:"keyword";s:24:"crispr therapeutics logo";s:5:"links";s:4552:"<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-un-convention-on-jurisdictional-immunities-of-states-and-their-property-commentary'>Un Convention On Jurisdictional Immunities Of States And Their Property Commentary</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-meter-reader-resume'>Meter Reader Resume</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-herschel-wallet-malaysia'>Herschel Wallet Malaysia</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-push-ups-vs-bench-press-study'>Push-ups Vs Bench Press Study</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-joanna-cherry-credit-card'>Joanna Cherry Credit Card</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-sergei-krikalev-age'>Sergei Krikalev Age</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-wendy-melvoin-purple-rain'>Wendy Melvoin Purple Rain</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-maya-rudolph-singing-prince'>Maya Rudolph Singing Prince</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-tradestation-2000'>Tradestation 2000</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-bok-choy-with-oyster-sauce'>Bok Choy With Oyster Sauce</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-brewdog-hotel-address'>Brewdog Hotel Address</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-rehabilitation-of-cerebral-palsy'>Rehabilitation Of Cerebral Palsy</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-bath-cbd-shop'>Bath Cbd Shop</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-magnolia-blossom-tree'>Magnolia Blossom Tree</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-organic-search-vs-paid-search'>Organic Search Vs Paid Search</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-ida-badaddr'>Ida Badaddr</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-kirribilli-woodfire-kitchen-menu'>Kirribilli Woodfire Kitchen Menu</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-luke-combs-beard-hat'>Luke Combs Beard Hat</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-dodo-videos'>Dodo Videos</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-duchesne-utah-weather'>Duchesne Utah Weather</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-how-big-is-australia-compared-to-alaska'>How Big Is Australia Compared To Alaska</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-kenan-thompson-movies'>Kenan Thompson Movies</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-eisbock-grain-bill'>Eisbock Grain Bill</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-patty-smyth-children'>Patty Smyth Children</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-is-cerebral-palsy-dominant-or-recessive'>Is Cerebral Palsy Dominant Or Recessive</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-mr-moto-movies-youtube'>Mr Moto Movies Youtube</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-what-is-organic-search-in-seo'>What Is Organic Search In Seo</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-abattoir-synonym'>Abattoir Synonym</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-you%27re-right'>You're Right</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-5150-studios'>5150 Studios</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-aix-en-provence-hotel'>Aix-en-provence Hotel</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-alive-2007-tour'>Alive 2007 Tour</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-wales-v-england-rugby-results-last-10-years'>Wales V England Rugby Results Last 10 Years</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-wheatsheaf-victoria'>Wheatsheaf Victoria</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-southwest-water-outages'>Southwest Water Outages</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-imf-argentina-loan'>Imf Argentina Loan</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-slag-heap-refers-to'>Slag Heap Refers To</a>,
<a href='https://africarisk.net/.tmb/docs/cxqkrdv.php?id=8cc357-what-does-apec-do'>What Does Apec Do</a>,
";s:7:"expired";i:-1;}